EAST RUTHERFORD, N.J. and MIAMI, Sept. 15 /PRNewswire-FirstCall/ -- Cambrex Corporation and DOR BioPharma, Inc. are pleased to announce that Chris Dale, Ph.D., Vice President, Technology, Cambrex Biopharmaceuticals business and Robert N. Brey, Ph.D., Chief Scientific Officer, DOR BioPharma will be speakers at the BioProcess International(TM) World 2005 Conference and Exhibition in Boston, Massachusetts, USA on Monday, September 19, 2005 at 11:45 am ET.
(Logo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO )
Dr. Dale and Dr. Brey will present a case study on the rational development of a cost effective manufacturing process for the production of RiVax(TM), a ricin vaccine developed by DOR BioPharma’s biodefense division. Cambrex is providing DOR with process development and cGMP production services. Cambrex successfully reengineered the low yielding and inefficient laboratory scale process and made a substantial improvement in productivity and yield of RiVax. The manufacturing process will be reviewed with respect to a cost of goods approach in the context of a vaccine procurement program.
Chris Dale, Ph.D., Vice President, Technology of the Cambrex Biopharma business, has over twenty years of experience in recombinant and native protein purification and over fifteen years experience of fermentation/cell culture in bacterial, yeast and mammalian systems gained in academic and industrial positions. Prior to joining Cambrex, Dr. Dale held positions at Covance Biotechnology Services and SmithKline Beecham. Dr. Dale holds a BSc in Microbiology from Coleg Prifysgol Cymru and a Ph.D. in Biochemistry from the University of Birmingham.
Dr. Robert Brey, Chief Scientific Officer, has been at DOR BioPharma since 1996. Previously, he held scientific and management positions in the Lederle-Praxis division of American Cyanamid, now a division of Wyeth. From 1996 through 1998, in addition to serving as Vice President of DOR BioPharma, he served as Corporate Vice President of InnoVaccines Corporation, a joint venture with Elan Pharmaceutical Technologies. From 1994 through 1996, Dr. Brey established the Vaccine Design Group to identify and develop novel vaccine technologies and platforms. Before entering into drug and vaccine delivery, he held senior scientific positions at Genex Corporation, one of the first biotechnology companies formed to exploit genetic engineering.
Dr. Brey received an undergraduate degree in biology from Trinity College in Hartford, Connecticut, his Ph.D. in microbiology from the University of Virginia and performed postdoctoral studies at MIT with Nobel laureate Salvador Luria. Dr. Brey is an inventor or co-inventor of ten U.S. patents in the area of vaccines.
For conference information, please visit http://www.ibclifesciences.com/BPI/US/.
About Cambrex
Cambrex is a global, diversified life sciences company dedicated to providing products and services to accelerate and improve the discovery and commercialization of human therapeutics. The Company employs approximately 1900 worldwide. For more information, please visit http://www.cambrex.com.
About DOR BioPharma, Inc.
DOR BioPharma, Inc. is a biopharmaceutical company focused on the development of therapeutic products and biomedical countermeasures for areas of unmet medical need. Their lead product, orBec(R) (oral beclomethasone dipropionate), is a potent, locally-acting corticosteroid being developed for the treatment of intestinal Graft-versus-Host disease (iGVHD), a common serious complication of bone marrow transplantation for cancer, as well as other gastrointestinal disorders characterized by severe inflammation. DOR BioPharma intends to file a new drug application (NDA) with the FDA for orBec(R) for the treatment of iGVHD later this year.
Through the BioDefense Division, DOR BioPharma is developing biomedical countermeasures pursuant to the paradigm established by the recently enacted Project BioShield Act of 2004. The biodefense products in development are bioengineered vaccines designed to protect against the deadly effects of ricin toxin and botulinum toxin, both of which are considered serious bioterrorism threats. The ricin toxin vaccine, RiVax(TM), is currently the subject of a Phase I clinical trial in normal volunteers. DOR BioPharma has also initiated a new botulinum toxin therapeutic development program based on rational drug design.
For further information regarding DOR BioPharma, please visit the Company’s website located at http://www.dorbiopharma.com.
RiVax(TM) and orBec(R) are trademarks of DOR Biopharma, Inc
Photo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comCambrex Corporation
CONTACT: Anne-Marie Hess, Director, Investor Relations & CorporateCommunications of Cambrex Corporation, +1-201-804-3062,annemarie.hess@cambrex.com
Company News On-Call: http://www.prnewswire.com/comp/134219.html /
